Navigation Links
Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
Date:5/14/2008

MONTVALE, N.J., May 14 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today reported its financial results for the first quarter ended March 31, 2008.

"We had a productive start to 2008, reporting significant progress with our collaborations and refocusing our operations to advance four high-value programs," said Vaughn M. Kailian, President and Chief Executive Officer. "Roche's recent decision to license R3487/MEM 3454 highlights the potential of the compound, provides a development path forward for our lead nicotinic alpha-7 receptor agonist, strengthens our financial profile and certainly validates our expertise in CNS drug development. We remain on track to achieve the following 2008 goals for each of our four major development programs: completing and announcing top-line results for our Phase 2a trial of R3487/MEM 3454 in cognitive impairment in schizophrenia and our Phase 1 program for R4996/MEM 63908, initiating a Phase 2a trial for MEM 1414, and advancing our 5-HT6 antagonist program into the clinic."

Financial Results

For the quarter ended March 31, 2008, the Company reported a net loss of $13.4 million, or $0.18 per share, compared to a net loss of $8.9 million, or $0.13 per share, for the same period in 2007.

For the quarter ended March 31, 2008, the Company reported revenue of $0.8 million, compared to revenue of $2.7 million for the same period in 2007. The decrease in revenue is a result of the conclusion of the research and development funding portion of the Company's collaboration with Amgen related to the development of PDE10 inhibitors.

Research and development expenses for the quarter ended March 31, 2008 were $11.0 million compared to $9.9 million for the same p
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Memory Pharmaceuticals to Announce First Quarter 2008 Results on Wednesday, May 14, 2008
2. Memory in artificial atoms
3. Memory Pharmaceuticals Receives Nasdaq Notification
4. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
5. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
6. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
7. Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
9. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
10. Memory Pharmaceuticals to Announce Third Quarter Results on Thursday, November 8, 2007
11. ASU researchers improve memory devices using nanotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... YORK , May 21, 2015  Susan ... Research (FPWR), a nonprofit organization dedicated to supporting ... Prader-Willi syndrome (PWS), announced today that FPWR has ... and Irina Shaulov contributed $1 million ... clinical initiatives.  ...
(Date:5/21/2015)... Germany (PRWEB) May 21, 2015 ... that its manufacturing facility in Worms, Germany has ... an independent subsidiary of the International Pharmaceutical Excipient ... Grace facilities that produce its SYLOID® FP brand ... received GMP certification, following the Curtis Bay, Maryland ...
(Date:5/21/2015)... - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: ... on the development of autologous cell therapies, announced ... Society for Cellular Therapy (ISCT) on RepliCel,s autologous ... a Phase 1/2 clinical trial.  The presentation, taking ... PM to 7:00 PM local time, will review ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 This year ... especially for lawns. US Patented Pearl’s Premium Ultra ... lawns around the country that are coming out of ... addresses a number of major global concerns related to ... “non-grass” grass – the alternative to the standard, water-wasting, ...
Breaking Biology Technology:The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2
... CALL DATE: Wednesday, Aug. 6, 2008 TIME: ... Dr. Candace Kendle, Chairman and CEO, ... call and,simultaneous webcast on Wednesday, Aug. 6 at 9:30 a.m. Eastern ... 30, 2008. A,question and answer session will follow., Webcast Instructions, ...
... BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced ... Daiichi Sankyo), has received marketing,approval from the Japanese ... label extension of Biopten(R) (sapropterin dihydrochloride), which,contains the ... for the,treatment of patients with phenylketonuria (PKU). BioMarin ...
... Consent Judgment Terminating Litigation --, MADISON, N.J., ... and,Impax Laboratories Inc. today announced that all conditions ... pertaining to Impax,s proposed,generic capsule formulation of Wyeth,s ... States District Court for the District of,Delaware. The ...
Cached Biology Technology:Kendle Invites You to Attend its Second Quarter 2008 Earnings Conference Call and Webcast 2Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU 2Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU 3Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU 4Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit 2Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit 3
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/143028 for MINIATURE, ... ENERGY TRANSFER  NXT-ID introduces a new ... This patent surrounds the use of miniature antenna ...
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... by a combination of genetic and environmental factors. For ... external influences. According to scientists from the Max Planck ... not harmful bacteria that trigger multiple sclerosis, but ... every human being needs for digestion. The researchers ...
... -- On Friday, Oct. 28 2011 the research icebreaker ... 200 scientists and technicians from research institutions in 14 ... They will examine a wide variety of topics: oceanography ... bacteria, tiny algae and animals all the way to ...
... DIEGO (Oct.27, 2011) The La Jolla ... fifth organization in the prestigious Sanford Consortium for ... for Biological Studies, The Scripps Research Institute, University ... Research Institute in the first-of-its-kind multi-institutional stem cell ...
Cached Biology News:Natural intestinal flora involved in the emergence of multiple sclerosis 2Natural intestinal flora involved in the emergence of multiple sclerosis 3RV Polarstern launches 28th Antarctic season 2La Jolla Institute joins Sanford Consortium for Regenerative Medicine 2La Jolla Institute joins Sanford Consortium for Regenerative Medicine 3
Request Info...
... are available in two product models - the ... models is that the 6000AT+ includes a membrane ... aerosol for improved detection limits and reduced oxides. ... range of elements by 10-40 times. Note that ...
... of RNase A-type ribonucleases Product Description: ,QIAGEN ... origin that binds noncovalently and inactivates a ... and C). It does not interfere with ... CL3. QIAGEN RNase Inhibitor inhibits greater than ...
... Radiolabeled Ligands\n\nReceptor-related research has long been enabled ... ligands selected to keep pace with new ... products and services for receptor research and ... If you do not find exactly what ...
Biology Products: